Related Experiment Videos
The ganglionic blocking properties of the cholinesterase reactivator, HS-6
Insights
Cholinesterase reactivator HS-6 exhibits ganglion-blocking properties. These effects, observed at doses relevant for soman poisoning treatment, may contribute to HS-6
Area of Science:
- Pharmacology
- Neuroscience
- Toxicology
Background:
- Cholinesterase reactivators are crucial for treating organophosphate poisoning, such as from soman.
- HS-6 is a potential therapeutic agent for nerve agent exposure.
- Understanding the full pharmacological profile of HS-6 is essential for its clinical application.
Purpose of the Study:
- To investigate the potential ganglion-blocking properties of the cholinesterase reactivator HS-6.
- To determine if these properties manifest at doses relevant for soman poisoning prophylaxis.
- To compare the ganglion-blocking effects of HS-6 with known agents like hexamethonium.
Main Methods:
- Intravenous administration of HS-6 in animal models.
- Measurement of blood pressure changes in response to various stimuli (carotid occlusion, vagal stimulation).
- Assessment of HS-6's effect on ganglionic neurotransmission using specific agonists (nicotine, dimethylphenylpiperazinium) and preganglionic stimulation.
Main Results:
- Intravenous HS-6 (30 mg/kg) caused a significant drop in blood pressure and reached high blood levels.
- HS-6 attenuated pressor responses to carotid occlusion and depressor effects of vagal stimulation.
- At sub-therapeutic doses for soman protection, HS-6 blocked nicotine and dimethylphenylpiperazinium effects, similar to hexamethonium but with lower potency.
Conclusions:
- HS-6 demonstrates significant ganglion-blocking properties.
- These properties are evident at doses relevant for potential use in soman poisoning.
- The ganglion-blocking action of HS-6 may contribute to its overall therapeutic benefits in organophosphate poisoning.
Abstract:
Following intravenous administration of the cholinesterase reactivator HS-6 (30 mg/kg), blood pressure fell (up to 50 mmHg) and maximal blood levels of HS-6 reached 242 microgram/ml. HS-6 attenuated the pressor response resulting from carotid occlusion and the depressor effect of vagal stimulation. Doses of HS-6 below those used to protect against soman in different animal species (10--30 mumol/kg) progressively blocked the ganglion-stimulating effects of nicotine and dimethylphenylpiperazinium but not the pressor effect following adrenaline, a pattern similar to that produced by hexamethonium but only 1/84 as potent. HS-6, like hexamethonium and mecamylamine, progressively blocked the contraction of the nictitating membrane of the cat resulting from preganglionic stimulation. The results indicate that HS-6 possesses ganglion-blocking properties at doses likely to be used in the protection against soman poisoning. The ganglion-blocking properties of the drug may be a factor in the beneficial effects of HS-6.